Trial
NCT03930771
Capecitabine and Temozolomide for Treatment of Recurrent Pituitary Adenomas
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Weill Medical College of Cornell University
Collaborators
—
Condition
Recurrent Pituitary Adenomas
Intervention
Capecitabine
Why stopped
the study had a low accrual rate
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-08-09